Charm Therapeutics

Charm Therapeutics

Private
London, EnglandHealthcare & Life Scienceswww.charmtx.com

Last Round

Series B

Sep 2, 2025

Total Funding Raised

$130M

Momentum Score

25 /100

Company Overview

CHARM Therapeutics is a biotechnology company that utilizes a deep learning platform to develop transformative medicines for patients, enabling doctors to effectively treat previously undruggable disease targets through advanced drug discovery technologies.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

AI drug discoverysmall molecule discoveryprotein-ligand co-foldingtechbio3D deep learningAI biotechDragonFoldundruggable targetsin silico drug discoverystructure-based drug discoverydrug discovery platformoncology drug discoverypharmaceutical partnershipslead optimizationhit discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Charm Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Charm Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BSep 2, 2025
VC RoundApr 14, 2023
Series AJun 9, 2022

Key People

Founding team and executive leadership

Laksh Aithani

Founder, CEO And Board Member

Founding Team

Laura Hare

Chief Operating Officer

Executive Team

Charm Therapeutics Investors

Notable investors and investment history

InvestorRounds
Braavos Investment AdvisersSeries A
New Enterprise Associates (NEA)Series B
Khosla VenturesSeries A, Series B
Grep VCSeries A
F-Prime CapitalSeries B, Series A
OrbiMedSeries B, Series A
General CatalystSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 8, 2025

    Dr. Erkut Bahceci appointed as the new Chief Medical Officer.

  • Sep 2, 2025

    $80M round completed.

Charm Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Charm Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Charm Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon, England
Employee Range33
Year Founded2021
Last FundingSep 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.